The Swiss pharmaceutical company Roche announced on February 8 that the company will expand its biopharmaceutical production capacity and will begin to reduce its small molecule drug production activities.
Roche does not disclose the company's capacity, but the company believes its capacity will be the largest in the industry. Company spokesperson Patrick Barth said: "We don't disclose capacity information, but we will definitely be the company with the largest biopharmaceutical capacity in the industry."
Roche's facilities include Basel/Kaiserauster in Switzerland, Penzberg/Munich in Germany, and Genentech in San Francisco, Oceanside and Vacaville, California, and Hillsboro, Oregon. As well as Singapore's production plant, the Japanese subsidiary, Chugai Pharmaceutical, has a production capacity of 49,000 liters of biopharmaceuticals in Tokyo.
Gradually expand biopharmaceutical capacity
The company's capacity expansion plan has been in progress: In 2013, Roche publicly stated that it invested 804 million US dollars in the company's biopharmaceutical production activities. In 2015, the company had planned to increase its biopharmaceutical capacity by 40%. In last week's annual investment report, company CEO Daniel O'Day pointed out that the company will continue to increase investment in capacity expansion, as this will determine the company's future business growth.
Just last week, Patheon NV, which has been acquired by Roche in the API business unit, said it has acquired a 300,000-square-foot API site in Florence with a 50-11,000 liter bioreactor that will become Patheon's The most important unit of API production and pilot business.
Reduced molecular drug production
Barth said: We will stop the operation of four underutilized small molecule drug manufacturing plants. In addition to Patheon, the plants in Spain, Italy and Clarecastle, Ireland have begun to close.
On February 1, Roche announced its annual financial data, which was calculated at a fixed exchange rate. The company's annual sales increased by 4%; in Swiss francs, it increased by 5%. Among them, pharmaceutical revenue increased by 3% (with the largest proportion of anticancer drugs Perjeta, Herceptin and Actemra/RoActemra), and Roche's diagnostic business revenue increased by 7%.
Elisa Microplate Reader,Laptop Diagnostic Machine,Elisa Microplate Reade,Elisa Immunoassay Machine
Guangdong Widinlsa International Co.Ltd , https://www.widinlsamachine.com